1
|
Wear MA, Hoppe BS, Moreno K, Bush A, Harrell AC, Peterson JL, Trifiletti DM, Attia A, Rutenberg MS, May BC, Vallow LA. Prompt Pain Relief: Advanced Practice Provider Led Rapid Access Palliative Radiotherapy Clinic. Int J Radiat Oncol Biol Phys 2023; 117:S60-S61. [PMID: 37784537 DOI: 10.1016/j.ijrobp.2023.06.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Patients (pts) commonly present to radiation oncology with painful bone metastases requiring urgent palliative radiotherapy (RT). Unfortunately, the pre-existing scheduling workflow for palliative referrals can be inefficient, causing significant delays before pts are seen by a radiation oncologist (RO). Our institution implemented an alternative workflow, which led to the creation of an advanced practice provider (APP) led Rapid Access Palliative RT Clinic (PRC). We investigated the impact of the PRC in reducing time from referral to consultation for pts in need of palliative RT. MATERIALS/METHODS In March 2022, we initiated an outpatient APP led PRC focused on the APP driving consultations supervised by the weekly on-call RO. Pts are offered a variety of options for consultation such as virtual, in clinic with reserved simulation time, and when appropriate virtual simulation, using diagnostic imaging for RT planning, and same day treatment requiring only one visit to the department. The clinic provides a point of contact that fosters multidisciplinary interaction and proactive continuity of care and follow up. Following institutional review board approval, pts who received palliative RT for painful bone metastases from June 2021 to December 2022 were retrospectively reviewed. Data was collected with respect to when the referral was placed for palliative RT and when the pts was seen for consultation by a provider. The cohort of pts seen between June 2022 and December 2022 represented the PRC cohort. A comparison cohort of pts treated between June 2021 and December 2021 represented the pre-PRC cohort. Unpaired T-test was used to analyze time from referral to consultation (TTC) between groups. P value < 0.05 was considered statistically significant. RESULTS During the pre-PRC period, 91 patients were treated, including 12 inpatients and 79 outpatients, while during the PRC period, 101 pts were treated, including 7 inpatients and 94 outpatients. The median dose was 8 Gy in 1 fraction for both cohorts. During the PRC period, there was a 19% increase in outpatients treated for bone metastases. Restricted to just outpatients, the average TTC was 10.4 days (SD 10.2) for pre-PRC cohort versus 6.3 days (SD 6.6) for the PRC cohort, which was statistically significant (p = 0.003). This was a 39% reduction in TTC. During the PRC period, 17 pts were not seen in the APP led PRC while 77 were seen in the PRC. The most common reason was an erroneous referral for curative intent treatment instead of palliative bone treatment. During the PRC period, those pts seen in the APP led PRC had an average TTC of 5.1 days (SD 4.6) versus 11.5 days (SD 10.64) for those not seen in the PRC (p = 0.03) with a 56% reduction in TTC. CONCLUSION The APP led PRC clinic significantly decreased time from referral to consultation for pts requiring urgent palliative RT for painful bone metastases. Further research is underway to determine if the PRC increases referrals, patients treated, patient satisfaction, and the impact on staffing RO.
Collapse
Affiliation(s)
- M A Wear
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - B S Hoppe
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - K Moreno
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - A Bush
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - A C Harrell
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - J L Peterson
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - D M Trifiletti
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - A Attia
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - M S Rutenberg
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - B C May
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - L A Vallow
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| |
Collapse
|
2
|
Laughlin BS, Corbin KS, Thorpe CS, Toesca DAS, Golafshar MA, McGee LA, Halyard M, Mutter RW, Keole SR, Park SS, Shumway D, Vallow LA, Vern-Gross TZ, Wong WW, DeWees TA, Vargas CE. Physician and Patient-Reported Outcomes of a Phase III Trial of Ultra-Hypofractionated vs. Moderate Hypofractionated Radiotherapy to the Whole Breast after Breast-Conserving Surgery. Int J Radiat Oncol Biol Phys 2023; 117:S6. [PMID: 37784534 DOI: 10.1016/j.ijrobp.2023.06.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To report a final analysis evaluating physician and patient-reported outcomes of early breast cancer patients receiving moderate hypofractionation or ultra-hypofractionated whole breast radiotherapy (RT). MATERIALS/METHODS Between April 4, 2018, and February 11, 2020, patients with localized breast cancer (T1-T3, N0-N1, and M0) managed with breast-conserving surgery (BCS) were enrolled. Patients were randomized to receive whole breast RT with moderate hypofractionation to 40 Gy in 15 fractions (Arm A) or ultra-hypofractionation to 25 Gy in 5 fractions (Arm B). An optional concurrent integrated boost to 48 Gy on Arm A or 30 Gy on Arm B was allowed. Early toxicity (<3 months), late toxicity (> 3 months), quality of life (QOL), cosmesis, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and deterioration of cosmesis were analyzed. RESULTS One hundred and seven patients were randomized to moderate hypofractionation (n = 54) or ultra-hypofractionation (n = 53). With a median follow-up of 36 months, no significant differences in patient characteristics were noted between the two arms. There were no patients with a grade ≥3 or higher toxicity. Grade 2 toxicities were 7.4% in Arm A and 7.5% in Arm B, and primarily consisted of radiation dermatitis (6 patients), fibrosis (1 patient) and lymphedema (1 patient). The average Harvard Cosmesis score and overall QoL were similar between arms at all time points, with no patients developing cosmetic deterioration. Patient-reported moderate to severe radiation skin burns were more commonly reported in Arm A (21.05%) vs. Arm B (6.25%) at the end of treatment (EOT) (p = 0.078). At EOT, patients receiving moderate hypofractionation had higher mean toxicity scores in breast tenderness (2.66 vs. 1.5, p = 0.018), skin flaking or peeling (0.63 vs. 0.06, p = 0.035), blistering (0.74 vs. 0.06, p = 0.028), pruritis (2.53 vs. 0.87, p < 0.001), erythema (4.24 vs. 2.0, p <0.001), telangiectasias (1.0 vs. 0.28, p = 0.021). Additionally, patients receiving moderate hypofractionation reported significantly worse changes from baseline at EOT in breast tenderness (-2.25 vs. -.86, p = 0.02), telangiectasia (-0.81 vs. 0.18, p = 0.012), skin discoloration (-4.31 vs. -1.04, p < 0.001), skin flaking or peeling (-.55 vs. 0.04, p = 0.053), blistering (-0.82 vs. -0.07, p = 0.033), and pruritus (-2.27 vs. -.67, p = 0.002). There was a return to baseline in all patient-reported breast domains by 3 months (p >0.05) in both arms. CONCLUSION Ultra-hypofractionated whole breast irradiation, consisting of 25 Gy in 5 fractions, provided comparable provider assessed toxicity and cosmetic outcomes to 40 Gy in 15 fractions. At the EOT assessment, ultra-hypofractionation had a better patient reported toxicity profile. Our findings provide further evidence to support daily ultra-hypofractionated whole breast radiotherapy as an appropriate treatment option for early-stage breast cancer.
Collapse
Affiliation(s)
- B S Laughlin
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - K S Corbin
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - C S Thorpe
- Department of Radiation Oncology, Sanford Health, Fargo, ND
| | - D A S Toesca
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - M A Golafshar
- Department of Qualitative Health Sciences, Section of Biostatistics, Mayo Clinic, Scottsdale, AZ
| | - L A McGee
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - M Halyard
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - R W Mutter
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - S R Keole
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - S S Park
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - D Shumway
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - L A Vallow
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - T Z Vern-Gross
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - W W Wong
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - T A DeWees
- Department of Qualitative Health Sciences, Section of Biostatistics, Mayo Clinic, Scottsdale, AZ
| | - C E Vargas
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| |
Collapse
|
3
|
Gunn HJ, DeWees TA, Voss MM, Corbin KS, Hallemeier CL, Stish BJ, Haddock MG, Petersen IA, Rule WG, Vallow LA, Brown PD, Olivier K, Trifiletti DM, Vargas CE, Ma DJ. Sensitivity of the PROMIS-10 for Capturing Radiation-Related Quality of Life Changes. Int J Radiat Oncol Biol Phys 2023; 117:e232-e233. [PMID: 37784929 DOI: 10.1016/j.ijrobp.2023.06.1149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Patient reported outcomes (PROs) are becoming more common when assessing the effects of radiotherapy (RT). The aim of this study was to assess the sensitivity of the Mental and Physical domains of the Patient-Reported Outcomes Measurement Information System 10 (PROMIS-10) to radiotherapy and determine what predictors were associated with change in quality of life. MATERIALS/METHODS Patients, regardless of cancer type, were enrolled on a multi-site prospective registry. Inclusion criteria included curative radiotherapy and completion of the PROMIS-10 prior to treatment (Baseline) and at End of Treatment (EOT). To assess the strongest predictors of change in the T score of mental and physical health, we included 14 demographic characteristics and treatment variables in a multivariable stepwise regression. RESULTS A total of 7,586 patients were eligible for the analysis. The median age was 65 (range 18-94), 54% were males, and 94% were white. A majority received photons (62.5%) and the others received protons (37.5%) with an average dose of 52.3 Gy (range 20-80 Gy) over an average of 22.6 fractions (range 1-66). Patient disease sites were sub-grouped into 12 categories: Breast (25.5%), GU (23.0%), H&N (11.1%), CNS (8.5%), Pancreas-Biliary (6.7%), Thoracic (5.7%), Soft Tissue/Bone (5.0%), Esophagus-Gastric (4.7%), Colorectal-Anus (4.4%), Heme/Lymph (2.6%), GYN (1.8%), and Skin/Melanoma (1.0%). For both outcomes, the model selected disease group as an important predictor and it explained the most variance in the outcome compared to the rest of the predictors. When probing the effect of disease group, H&N, Esophagus-Gastric, Skin/Melanoma, and Colorectal-Anus had the largest mean decrease in quality of life for both domains. For mental health, the model also selected radiation type. Patients treated with protons indicated a bigger decrease in mental health compared to patients treated with photons (b = 0.43, 95% CI: -0.01, 0.69). For physical health, the model selected total fractions, ethnicity, and T stage. As number of fractions increased, the physical health change scores became more negative, on average (b = -0.03, 95% CI: -0.05, -0.01). Hispanic/Latino patients indicated a smaller decrease in physical health compared to White (b = -1.50, 95% CI: -2.60, -0.40) and Unknown ethnicity patients (b = -1.82, 95% CI: -3.36, -0.27). Finally, patients with a T stage of 3 or greater indicated a smaller decrease in physical health than patients with a T stage less than 3 (b = 0.76, 95% CI: 0.35, 1.16). CONCLUSION The PROMIS-10 did not capture significant change for patients undergoing curative radiotherapy except for patients with Head & Neck, Esophagus-Gastric, Skin, and Colorectal-Anus cancer. Further analyses should explore which patients experience the greatest change in quality of life within disease group.
Collapse
Affiliation(s)
| | - T A DeWees
- Department of Qualitative Health Sciences, Section of Biostatistics, Mayo Clinic, Scottsdale, AZ
| | - M M Voss
- Department of Quantitative Health Sciences, Mayo Clinic, Arizona, Phoenix, AZ
| | - K S Corbin
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | | | - B J Stish
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - M G Haddock
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - I A Petersen
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - W G Rule
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - L A Vallow
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - P D Brown
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - K Olivier
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - D M Trifiletti
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - C E Vargas
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - D J Ma
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| |
Collapse
|
4
|
Bush A, Herchko S, Chellini A, Orande CL, Harrell AC, Wear MA, Rutenberg MS, Attia A, Trifiletti DM, Peterson JL, May BC, Vallow LA, Hoppe BS. Prompt Pain Relief from Bone Metastases: Mature Results from the Virtual Simulation Program. Int J Radiat Oncol Biol Phys 2023; 117:e91-e92. [PMID: 37786213 DOI: 10.1016/j.ijrobp.2023.06.850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Rapidpain relief for patients with bone metastases can be a challenge due to the lengthy and complex radiotherapy workflow. The purpose of this study was to evaluate the time (in days) between initial radiation oncology consultation and start of palliative radiation treatment after implementing an alternative virtual simulation palliative workflow. MATERIALS/METHODS Patients meeting strict criteria were selected for virtual simulation, which included only those with painful bone metastases who were recommended palliative radiotherapy using standard AP/PA or opposed lateral fields. A recent (within 30 days) diagnostic CT scan clearly visualizing the target volume was required for treatment planning. For comparison, a reference group of 40 consecutive patients with bone metastases that underwent in-person CT simulation prior to virtual simulation implementation was reviewed. RESULTS Forty-five patients were treated for painful bone metastases as part of the virtual simulation program from May 2021 to October 2022. Regarding travel distance, 23 patients lived locally (<50 miles from treatment center) and 22 patients were distant (≥50 miles from treatment center). Average time from consult to treatment for all virtual simulation patients was 3.7 days compared to 7.5 days for in-person CT simulation patients (3.8 days sooner on average, p = <0.001). For outpatient treatments, average time from consult to treatment for distant virtual simulation patients was 4.0 days compared to 8.9 days for distant in-person CT simulation patients (4.9 days sooner on average, p = 0.003). CONCLUSION The virtual simulation program decreased the time from consult to start of treatment for patients recommended palliative radiotherapy for painful bone metastases by over 50%. This benefit was most significant for outpatients traveling ≥ 50 miles for treatment. Virtual simulation-based planning can be considered for patients anxious to proceed with radiotherapy quickly, or in underserved settings with limited transportation options to regional treatment centers.
Collapse
Affiliation(s)
- A Bush
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - S Herchko
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - A Chellini
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - C L Orande
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | | | - M A Wear
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - M S Rutenberg
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - A Attia
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - D M Trifiletti
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - J L Peterson
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - B C May
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - L A Vallow
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| | - B S Hoppe
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
| |
Collapse
|
5
|
Vicini FA, Cecchini RS, White JR, Julian TB, Arthur DW, Rabinovitch RA, Kuske RR, Parda DS, Ganz PA, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, Costantino JP, Bear HD, Germaine I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ, Wolmark N. Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs4-04] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Conventional WBI after lumpectomy for early-stage breast cancer decreases ipsilateral breast tumor recurrence (IBTR), yielding comparable results to mastectomy. Accelerated PBI appears effective in reducing IBTR by treating only the tumor bed area. As the majority of IBTR occur at or in the vicinity of the tumor bed, we hypothesized that PBI would be as effective as WBI in controlling IBTR. The primary aim of NSABP B-39/RTOG 0413 was to determine if PBI provides equivalent local tumor control post lumpectomy compared to WBI in pts with early-stage breast cancer. The equivalency test was based on a 50% margin of increase in the hazard ratio (HR=1.5). Secondary endpoints included: overall survival (OS), recurrence-free interval (RFI), distant disease-free interval (DDFI), and toxicity.
Methods: Eligible pts had lumpectomy with histologically-free margins and 0-3 positive axillary nodes. Pts were stratified by stage, menopausal status, hormone receptor status, and intent to receive chemotherapy and then randomized to PBI or WBI. PBI was 10 fractions of 3.4-3.85 Gy, given twice daily with either brachytherapy or 3D external beam radiation. WBI was 50 Gy in 2 Gy fractions given daily with a sequential boost to the surgical cavity. Follow-up was every 6 mos for 5 yrs and then annually. All analyses were by intent-to-treat.
Results: From 3-21-05 to 4-16-13, 4216 pts were randomized: 2107 PBI; 2109 WBI. 61% were postmenopausal; 81% were hormone receptor-positive; 29% intended to receive chemotherapy. Stage distribution was: DCIS, 24%; invasive pN0, 65%; invasive pN1, 10%. As of 7-31-18, median follow-up was 10.2 yrs. There were 161 IBTRs as first events: 90 PBI v 71 WBI (HR 1.22; 90%CI 0.94-1.58). Per protocol-defined margin, to declare PBI and WBI equivalent regarding IBTR risk, the 90% CI for the observed HR had to lie entirely between 0.667 and 1.5. The percent of pts IBTR-free at 10 yrs was 95.2% PBI v 95.9% WBI. A statistically significant difference in the 10-yr RFI rate favored WBI (91.9% PBI v 93.4% WBI; HR 1.32; 95%CI 1.04-1.68; p=0.02). No statistically significant differences existed between PBI and WBI in DDFI (HR 1.31; 95%CI 0.91-1.91; p=0.15), OS (HR 1.10; 95%CI 0.90-1.35; p=0.35), or DFS (HR 1.12; 95%CI 0.98-1.29; p=0.11). Grade 3 toxicity was 9.6% PBI v 7.1% WBI, and grade 4-5 toxicity was 0.5% v 0.3%, respectively.
Discussion: PBI did not meet the criteria for equivalence to WBI in controlling IBTR based on the upper limit of the hazard ratio confidence interval. However, the absolute difference in 10-yr rate of IBTR was <1% (4.8% PBI v 4.1% WBI). The risk of an RFI event was statistically significantly higher for PBI compared to WBI, but the absolute difference in 10-yr RFI rate was also small (8.1% PBI v 6.6% WBI). DDFI, OS, and DFS were not statistically different for PBI v WBI. Grade 3-5 toxicities, although low, were more common for PBI than WBI. The trial population was heterogeneous, ranging from Stage 0-2 breast cancer, and outcome by risk categories are being analyzed.
Support: U10CA180868, -180822, UG1CA189867.
Citation Format: Vicini FA, Cecchini RS, White JR, Julian TB, Arthur DW, Rabinovitch RA, Kuske RR, Parda DS, Ganz PA, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, Costantino JP, Bear HD, Germaine I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran, Jr. WJ, Wolmark N. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS4-04.
Collapse
Affiliation(s)
- FA Vicini
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - RS Cecchini
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - JR White
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - TB Julian
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - DW Arthur
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - RA Rabinovitch
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - RR Kuske
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - DS Parda
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - PA Ganz
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - MF Scheier
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - KA Winter
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - S Paik
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - HM Kuerer
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - LA Vallow
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - LJ Pierce
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - EP Mamounas
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - JP Costantino
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - HD Bear
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - I Germaine
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - G Gustafson
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - L Grossheim
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - IA Petersen
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - RS Hudes
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - WJ Curran
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| | - N Wolmark
- NRG Oncology, Pittsburgh; MHP Radiation Oncology Institute St. Jospeh's Mercy Hopsital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), K
| |
Collapse
|
6
|
Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky A, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Abstract S6-04: Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-s6-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The clinical results of NSABP B-35, phase III trial comparing 1 mg/day A to 20 mg/day tam, each given for 5 years, were reported at ASCO 2015. B-35 demonstrated a statistically significant benefit in breast cancer free interval for women assigned to A, primarily in women <60 years. A secondary endpoint of B-35 was quality of life (QOL) and symptom (SX) outcomes in the two treatment groups. The primary hypotheses of the PRO study were that there would be no differences in QOL between the two treatments, and that patients receiving A would report higher rates of hot flashes compared to patients receiving tam. Other SX comparisons were secondary endpoints.
Methods
QOL and SX were assessed at baseline (prior to randomization), and every 6 months thereafter for 5 years of treatment and in the following 12 months. QOL was measured with the SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS). SX were measured with selected scales from the BCPT symptom-checklist, and other standardized instruments. Stratification was by age (<60 v ≥60) as in the main trial. Study hypotheses and endpoints were examined by comparing PROs in the two treatment arms using a mixed model for repeated measures analysis with adjustment for the baseline scores, time point and age category, using an intention-to-treat principle and including only patients who completed the baseline and at least one follow-up questionnaire. Patients with protocol events were censored. Only data through 60 months are reported here. The accrual goal for the sub-study was 1,150 consecutive patients.
Results
Between January 6, 2003 and June 15, 2006, a total of 3,104 patients were entered and randomly assigned to NSABP Protocol B-35. Accrual to the PRO study of B-35 closed on December 28, 2004, at which time 1,275 patients were entered, with 1,193 patients included in this analysis. There were no medical or demographic differences between patients assigned to A or tam in the PRO sub-study, and they reflected the characteristics of the parent trial. Adherence to data collection across the 60 months was 87%. There were no significant differences in QOL outcomes by treatment for the PCS (p=0.16) or the MCS (p=0.38). SX subscales: hot flash scale was greater in tam group and this difference varied over time (p=0.001); musculoskeletal pain was significantly greater in A group for time points 6-24 months (all p<.001); vaginal problems were greater in A group (p=0.03). Hot flash and vaginal problems were significantly worse in women <60 years. Additional SX outcomes (depression, fatigue, sexual function) will be reported at presentation.
Conclusion
In this large, double-blind, placebo-controlled trial comparing A to tam in patients with DCIS, there was no significant difference in QOL between the two treatments. However, there were important treatment differences in SX outcomes, which should be considered as part of treatment decision-making discussions, along with the clinical breast cancer outcome results.
Support: CA-180868, 180822, 189867, 196067, 114732; AstraZeneca Pharmaceuticals LP.
Citation Format: Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky A, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr S6-04.
Collapse
Affiliation(s)
- PA Ganz
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - RS Cecchini
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - TB Julian
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - RG Margolese
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - JP Costantino
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - LA Vallow
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - KS Albain
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - PW Whitworth
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - ME Cianfrocca
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - A Brufsky
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - HM Gross
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - GS Soori
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - JO Hopkins
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - L Fehrenbacher
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - K Sturtz
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - TF Wozniak
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - TE Seay
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - EP Mamounas
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| | - N Wolmark
- NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cance Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health
| |
Collapse
|
7
|
Chumsri S, Necela BM, Ordentlich P, Advani P, Moreno-Aspitia A, McLaughlin SA, Geiger X, McDonough M, Vallow LA, Perez EA, Thompson EA. Abstract P2-04-02: Immunomodulatory effects of entinostat on PD-L1 and MHC class I and II in different subtypes of breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-04-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Targeting immune checkpoint programmed death receptor 1 (PD-1)/PD-L1 pathway has shown promising clinical activity with some preliminary association of clinical benefit with PD-L1 expression on tumors. Recent preclinical and clinical studies highlight the beneficial immunomodulatory potential of epigenetic therapy. Entinostat is a class I specific histone deacetylase inhibitor (HDACi). A promising preclinical study showed that entinostat in combination with immune checkpoint blockade agent can eradicate modestly immunogenic breast tumors in mice via reduction in immunosuppressive myeloid-derived suppressor cells. In this study, we investigated the effects of entinostat on expression of immune-related genes in breast cancer cells to further explore the potential mechanism of its combined activity.
Method: Gene expression was assessed on Nanostring platform using the nCounter GX Human ImmunologyV2 panel comprised of 594 immune-related and 15 reference genes. Gene expression was normalized to the internal positive controls and reference genes using nSolver2.0 software. Hormone receptor-positive (HR+) breast cancer (MCF-7 and T47D) and triple negative breast cancer (TNBC) cell lines (MDA-MB-231 and Hs578T) were used for the analysis. Gene expression analysis was performed on control and after 24-hour treatment of entinostat at clinically relevant 125 and 500 nM concentrations.
Results: Overall, a greater number of immune-related genes were induced > 2 fold with entinostat at 125 and 500 nM in TNBC compared to HR+: 77 and 118 genes in MDA-MB-231, 80 and 147 genes in Hs578T, 20 and 64 genes in MCF-7, and 73 and 72 genes in T47D, respectively. In particular, MHC class I (HLA-A, HLA-B, HLA-C) and II (HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA, and HLA-DRB1) genes were induced by entinostat in a dose dependent manner (range 1.5-22.44 fold). These inductions were observed in both HR+ and TNBC cell lines. Interestingly, we found higher baseline expression and a several fold increase in PD-L1 expression in TNBC. PD-L1 mRNA expression increased by 1.74 and 2.14 fold in MDA-MB-231 and 3 and 9.6 fold in Hs578T with 125 and 500 nM treatment, respectively. Corresponding increase in PD-L1 protein expression after entinostat treatment was also observed. In contrast, there appeared to be no significant changes in PD-L1 expression after entinostat treatment in MCF-7 and T47D. Furthermore, we also identified 21 genes that were differentially induced by entinostat in TNBC but not in HR+. These genes include PTPN22, ARG2, CISH, IL17A, ICAM2, KIR3DL1, CXCR3, TLR2, CFD, CCR5, IL13, LILRA3, IL8, TNFRSF9, DPP4, MR1, SELPLG, PTGS2, IL1B, CD3D, and MBL2. No significant change in PDL2 expression was observed in any of the cell lines.
Conclusion: Our data suggest that entinostat induces immune-related genes involved in antigen presentation in both ER+ and TNBC cells, potentially increasing the immunogenicity of these tumors. Given the significant induction of PD-L1 expression with entinostat in TNBC, our preclinical data provides support for further investigation of entinostat in combination with anti-PD1 or anti-PD-L1 in this subtype of breast cancer.
Citation Format: Chumsri S, Necela BM, Ordentlich P, Advani P, Moreno-Aspitia A, McLaughlin SA, Geiger X, McDonough M, Vallow LA, Perez EA, Thompson EA. Immunomodulatory effects of entinostat on PD-L1 and MHC class I and II in different subtypes of breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-04-02.
Collapse
Affiliation(s)
- S Chumsri
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - BM Necela
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - P Ordentlich
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - P Advani
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - A Moreno-Aspitia
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - SA McLaughlin
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - X Geiger
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - M McDonough
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - LA Vallow
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - EA Perez
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| | - EA Thompson
- Mayo Clinic, Jacksonville, FL; Syndax Pharmaceuticals, Inc., Waltham, MA
| |
Collapse
|
8
|
Bernard JR, Vallow LA, McNeil RB, McLaughlin SA, Geiger XJ, Perez EA. In newly diagnosed breast cancer, is a contralateral prophylactic mastectomy necessary following a negative MRI? J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.627] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
627 Background: With more centers using MRI to aid in initial staging, there is apprehension that the highly sensitive MRI exam may lead to “unnecessary” mastectomies. We evaluated whether a negative contralateral MRI could be used to rule out a synchronous contralateral carcinoma and hence avoid a prophylactic contralateral mastectomy (CPM) at initial breast cancer diagnosis. Methods: Data of women with a new diagnosis of breast cancer (invasive or DCIS) from February 2003-November 2007 at our institution were reviewed. Women who had a negative MRI of the contralateral breast and who subsequently underwent CPM were included. A CPM was one in which there was no histological confirmation of cancer in the contralateral breast before surgery. All mastectomy specimens were analyzed pathologically. True negatives were mastectomy samples which contained no cancer following pathologic examination. False negatives were mastectomy samples which were found to have cancer after pathologic review. Results: 538 women were identified. 51 women met the study criteria. Median patient age was 56 years (range, 33–77). Of the 51 women who underwent a CPM, 2 were found to have pathologic confirmation of cancer. One occult cancer was a 0.3 cm grade 1, invasive lobular carcinoma; the second a 0.5 cm, low grade DCIS. The overall prevalence of synchronous occult contralateral cancer after a negative MRI was 3.9% (95% CI 0.5 - 13.5%). The negative predictive value of MRI was 96.1% (95% CI 86.5 - 99.5%). Conclusions: This study provides pathologic data regarding the utility of a negative contralateral breast MRI in women with newly diagnosed breast cancer. The prevalence of a synchronous occult contralateral cancer after a negative MRI in women with newly diagnosed breast cancer is very low. Physicians and patients can be assured that the risk of occult cancer is low in the setting of a normal contralateral MRI, an important fact when considering CPM after a diagnosis of unilateral breast cancer. No significant financial relationships to disclose.
Collapse
|
9
|
Hines SL, McLaughlin SA, Vallow LA. MRI findings in women with triple negative breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-4014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #4014
Background
 Preoperative magnetic resonance imaging (MRI) of the breasts in women with breast cancer (BC) has improved the detection of occult ipsilateral (I/L) and contralateral (C/L) malignancies. Breast MRI findings in patients with estrogen receptor (ER), progesterone receptor (PR), and HER2 negative (triple negative (TN)) disease have not been previously reported. Women with TN BC are at increased risk of distant metastases and a reduced survival vs. BC patients as a whole. One potential explanation may be the presence of occult disease. The role of bilateral breast MRI in these patients remains to be determined.
 Hypothesis
 Patients with TN BC are more likely to have occult malignancy identified by preoperative MRI vs. those with non-TN BC.
 Methods
 All newly diagnosed BC patients from 2003-2007 were reviewed. Information on age, race, histology, ER, PR, HER2, staging, treatment, MRI findings, subsequent investigations, and additional cancer diagnoses was recorded. The incidence of additional I/L or C/L malignany was calculated. The percentage of total patients initially felt to be candidates for partial breast irradiation who required a change in their cancer management was calculated.
 Results
 55 (11%) were diagnosed with TN BC, of whom 52 women completed preoperative MRI. 456 (89%) had non-TN BC; 421 completed preoperative MRI. The median age among TN and non-TN patients was 62 years (Table 1). A majority of women in both groups were Caucasian. African-American women were more likely to be diagnosed with TN vs. non-TN disease (11% vs. 6%).
 
 I/L BC was documented in 13/52 (25%) of TN patients vs. 25% of non-TN patients. No C/L cancers were detected in the TN group (6% in the non-TN group). Of the TN group, 15 patients required a change in their treatment (29%) based on findings from MRI vs. 32% of non-TN patients.
 Conclusions
 Patients with a new diagnosis of TN BC are not at increased risk of occult malignancy than those with non-TN BC. 25% of patients with TN BC had additional I/L disease not previously detected on clinical examination, mammogram, or ultrasound. Of those with non-TN BC, 25% were diagnosed with an additional I/L and 6% with C/L malignancy. The benefit of MRI was limited by false positives, with a number of patients in both groups undergoing a benign biopsy.
 These results suggest that patients with TN BC are not more likely than those with non-TN disease to have additional occult I/L or C/L cancer. The incidence of additional disease remains high and preoperative MRI may be beneficial.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4014.
Collapse
Affiliation(s)
- SL Hines
- 1 Multidisciplinary Breast Clinic, Mayo Clinic, Jacksonville, FL
| | - SA McLaughlin
- 1 Multidisciplinary Breast Clinic, Mayo Clinic, Jacksonville, FL
| | - LA Vallow
- 1 Multidisciplinary Breast Clinic, Mayo Clinic, Jacksonville, FL
| |
Collapse
|
10
|
Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 2008; 19:1561-5. [PMID: 18534964 DOI: 10.1093/annonc/mdn283] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Women with triple-negative (TN) breast cancer are at increased risk of distant metastases and have reduced survival versus other breast cancer patients. Relative survival of women with TN breast cancer who develop brain metastases is unknown. METHODS Patients with breast cancer who developed brain metastases at our institution from 1993 to 2006 were reviewed. Four survival time intervals were compared in patients with TN disease and those with non-TN disease: initial diagnosis to distant metastases, distant metastases to brain metastases, brain metastases to death, and overall diagnosis to death. RESULTS One hundred and eighteen patients were identified. Fifty-one (50%) of 103 were estrogen receptor positive, 26 (39%) of 67 were human epidermal growth factor receptor 2 positive, and 20 (22%) of 91 were TN. Survival times were shorter for TN patients, with overall survival of 26 months in TN patients versus 49 months for non-TN patients. In TN patients, time to development of distant metastases, brain metastases, and death after brain metastases was shorter than in non-TN patients. CONCLUSION Patients with TN disease were more likely to develop distant metastases earlier than non-TN patients, developed brain metastases sooner, and had shorter overall survival.
Collapse
Affiliation(s)
- S L Hines
- Division of General Internal Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
| | | | | | | | | | | |
Collapse
|
11
|
Bernard JR, Vallow LA, DePeri ER, Feigel DG, Amar S, Buskirk SJ, Perez EA. Mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging in the elderly. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Bernard JR, Vallow LA, Packianathan S, Feigel DG, DePeri ER, Buskirk SJ, Perez EA. Identification of risk factors in mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging (MRI). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
614 Background: An analysis of preoperative bilateral breast MRI at our institution suggests that approximately 1/3 of patients with newly diagnosed breast cancer may have a mammographically occult, but MRI-evident, contralateral breast abnormality. A number of these patients will have pathologic confirmation of carcinoma in the contralateral breast. Identification of risk factors to predict which patients are at high risk for having a mammographically occult contralateral carcinoma was performed. Methods: MRI results of 401 women with newly diagnosed breast carcinoma who underwent MRI were reviewed (overall group; OG). Patients with a contralateral abnormality identified only by MRI were analyzed to determine the incidence of contralateral carcinoma. In addition, the following risk factors were evaluated: Age at diagnosis, menopausal status, tumor size, nodal status, ipsilateral tumor histology, tumor grade, hormone receptor status, Her-2/neu receptor status, and whether the patient had a palpable vs. mammographically detected abnormality. Results: Pathologically confirmed contralateral carcinoma (CC) was found in 13 patients (3.2%). Similar percentages of patients in both groups (OG and CC) were noted in regard to tumor size, histology, grade, nodal status, Her-2/neu receptor status, and method of detection (palpable vs. mammographic). However, median patient age was 71 (CC) vs. 62(OG); 92% (12/13) were postmenopausal (CC) compared to 75% (OG); and 100% were ER positive (CC) vs. 81% percent (OG). Conclusions: Older, postmenopausal women who have ER + tumors may have a higher likelihood of having synchronous, contralateral, mammographically occult, MRI-detected breast carcinoma. Preoperative MRI may be beneficial in patients with similar risk factors; however, further follow up and additional experience is needed for confirmation of these findings. No significant financial relationships to disclose.
Collapse
|
13
|
Vallow LA, Packianathan S, Deperi ER, McDonough MD, Earle JD, Perez EA. Pre-operative breast magnetic resonance imaging (MRI) influences patient selection for partial breast irradiation. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.604] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
604 Background: Many patients with localized breast cancer undergo breast conservation therapy. Partial breast irradiation (PBI) is a technique that reduces irradiated tissue volume and decreases treatment time. Appropriate patient selection for this technique is critical. We studied the influence of pre-operative breast MRI on patient selection for PBI. Methods: Between 05/04 and 05/05, 231 women with newly diagnosed breast cancer underwent pre-operative bilateral breast MRI (median age = 64, range 34 to 89). Following initial clinico-pathologic review, patients were deemed to be eligible for PBI based on the NSABP B39 protocol if they satisfied its inclusion criteria (tumor size ≤3 cm, ≤3 positive nodes, negative surgical margins, lack of multicentric disease), derived through physical examination, mammography and/or ultrasonography. Breast MRI scans of all patients deemed eligible for PBI by these criteria were then reviewed to determine the impact of the MRI findings on their eligibility for PBI. Only patients who had pathological assessment to correlate with the MRI findings were included in the analysis. Results: Based on the NSABP B39 inclusion criteria, 186 patients (81%) were considered to be appropriate candidates for PBI without influence from MRI findings. Of these 186 women, MRI findings led to pathologically proven additional disease that altered the recommendations for PBI in 26 patients (14%). Mammographically occult, biopsy proven multicentic disease was detected in the ipsilateral breast in 13 patients (7%), whereas 5 women (2.7%) had mammographically occult, biopsy proven multicentric disease in the contralateral breast. In 8 patients (4.3%), pathological assessment confirmed more extensive local disease than was detected by breast MRI. Conclusions: Up to 14% of patients initially deemed eligible for PBI were later found to be ineligible because of breast MRI findings. Ipsilateral multicentric disease was identified in 7%, contralateral disease was discovered in 2.7%, and more extensive local disease was noted in 4.3%. Bilateral breast MRI complements other imaging modalities in determining eligibility for PBI by identifying mammographically occult disease in patients for whom PBI may be inappropriate. No significant financial relationships to disclose.
Collapse
|